Choline alfoscerate
Phase 3Small molecule
Chong Kun Dang PharmaceuticalCholine alfoscerate is one of 5 small molecule programs targeting Mild to Moderate Alzheimer's Disease. It is currently in Phase 3.
1
Indications
6
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Mild to Moderate Alzheimer's Disease
#DrugCompanyPhaseTrials
1Choline alfoscerate
Chong Kun Dang PharmaceuticalPhase 3
Sodium Pentaborate
TTabriz University of Medical Sciences
Phase 2
Neuroepo
IInternational Center for Neurological Restoration, Cuba
Phase 2
RB-ADSC
RRegeneration Biomedical, Inc.
Phase 1
RO7126209
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cognitive impairment3 trials
Injury1 trial
Mild to Moderate Alzheimer's Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Choline alfoscerate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details